Featured Trial:
Pancreatic Cyst Monitoring

Featured Trial:
Myeloma Treatment

Featured Trial:
Lung Cancer Treatment

Featured Trial:
Sarcoma Treatment

Featured Trial:
Blood Cancer (Lymphoma)
Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

September 9, 2025

Categories

News Stories

Dr. Suzanne Cole on using real-world data to improve the generalizability of clinical trial results (highlights PrE1702 and EA5182)

September 8, 2025

Categories

News Stories

EA5181 trial finds no survival benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable non-small cell lung cancer

August 28, 2025

Categories

The August 2025 News from ECOG-ACRIN blog is now available

August 20, 2025

Categories

Announcements

The ECOG-ACRIN Clinical Research Associates (CRA) Core Committee is seeking candidates

August 14, 2025

Categories

News Stories

Mental health disparities persist 2 years after DCIS surgery (E4112)

Posts

ECOG-ACRIN Cancer Research Group Follow 8,326 6,417

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

17h 1965822769674723474

In #ClinicalTrial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: https://bit.ly/EA7222 #sarcomaawareness

Reply on Twitter 1965822769674723474 Retweet on Twitter 1965822769674723474 0 Like on Twitter 1965822769674723474 0 Twitter 1965822769674723474

ECOG-ACRIN Cancer Research Group @eaonc ·

18h 1965813365491880060

ICYMI: Check out our round-up of recently published
@eaonc research results. More here ➡️ https://bit.ly/aug25research #EAOnc

Reply on Twitter 1965813365491880060 Retweet on Twitter 1965813365491880060 0 Like on Twitter 1965813365491880060 0 Twitter 1965813365491880060

ECOG-ACRIN Cancer Research Group @eaonc ·

18h 1965807773070905522

Do you have squamous cell carcinoma of the head and neck that has spread to a limited number of places? If so, you may be eligible to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea3211-study #HeadAndNeckCancer #HNSCC

Reply on Twitter 1965807773070905522 Retweet on Twitter 1965807773070905522 0 Like on Twitter 1965807773070905522 0 Twitter 1965807773070905522

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).